Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Letters to the Editor

Diabetes, Hypertension, and Cardiovascular Disease: An Update

Franz H. Messerli, Ehud Grossman
Download PDF
https://doi.org/10.1161/01.HYP.38.3.e11
Hypertension. 2001;38:e11
Originally published September 1, 2001
Franz H. Messerli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ehud Grossman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • References
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

To the Editor:

Sowers et al are to be commended for writing a thorough review on the diabetic hypertensive patient.1 In doing so, they came to the conclusion that, “Results of the SHEP) [2] and the UKPDS) [3] trials suggest that diuretics and β-blockers as well as ACE inhibitors are also useful therapeutic agents in diabetic hypertensive patients who often require ≥2 drugs to control blood pressure adequately. [4]”) Although we agree with this statement, it should be pointed out that β-blockers seem to be far less efficacious than the other drug classes in this subpopulation. The UKPDS (UK Prospective Diabetes Study) has demonstrated that coronary heart disease is much more prevalent than cerebrovascular disease in the diabetic hypertensive patient. In fact, in the UKPDS, morbidity and mortality events from coronary heart disease were between 4 to 6 times more common than events from cerebrovascular disease. Thus, any drug class used to treat the hypertensive diabetic population should exert some primary cardioprotective efficacy, ie, lower the risk of coronary heart disease. Unfortunately, antihypertensive therapy in the UKPDS had no effect on coronary artery disease (Figure). As Sowers et al pointed out, half of these patients were treated with an ACE inhibitor (captopril) and half with a β-blocker (atenolol), but there was no significant difference between the 2 treatment strategies. Similar to our previous findings in hypertension in the elderly,5 β-blockers failed to exert a primary cardioprotective effect in the diabetic patient in the UKPDS. Further, β-blockers have well-documented detrimental effects on metabolic findings, increase the risk of diabetes in nondiabetic hypertensive patients,6 and cause weight gain,7 all of which increase the risk of coronary heart disease and other cardiovascular morbidity and mortality. Because coronary artery disease is the most prevalent cardiac complication in these patients, β-blockers should be used with restraint only in patients with specific indications.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

References

  1. ↵
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. . 2001; 37: 1053–1059.
    OpenUrlAbstract/FREE Full Text
  2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. . 2000; 342: 145–153.
    OpenUrlCrossRefPubMed
  3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, UK Prospective Diabetes Study Group. BMJ. . 1998; 317: 703–713.
    OpenUrlAbstract/FREE Full Text
  4. Sowers JR, Reed J. Clinical advisory treatment of hypotension in diabetes. J Clin Hypertens. . 2000; 2: 132–133.
    OpenUrl
  5. ↵
    Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. . 1998; 279: 1903–1907.
    OpenUrlCrossRefPubMed
  6. ↵
    Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med. . 2000; 342: 905–912.
    OpenUrlCrossRefPubMed
  7. ↵
    Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. . 2001; 37: 250–254.
    OpenUrlAbstract/FREE Full Text

Response

I have reviewed the comments made by Drs Messerli and Grossman regarding our review on diabetes and hypertension published recently in Hypertension.1 Although our review emphasized rigorous treatment of hypertension and the importance of ACE inhibitor therapy as an important component, it did not focus on β-blockers. Indeed, we emphasized that calcium antagonists, low-dose diuretics, and β-blockers were all appropriate medications for the diabetic population, who often need 2 to 3 classes of hypertensive medication. Given the high prevalence of ischemic heart disease in the diabetic patient, β-blockers were an important component of the armatarium. Although they can cause a small weight gain, so does insulin, sulfonylurea, and thiazolidinedione therapy for hyperglycemia, but that does not preclude their use. Also, prior concern regarding adverse effects of β-blockers on hypoglycemia and masking of symptoms increasingly appears to be important for only some type 1 diabetics. Accordingly, we do not believe the negative remarks regarding use of β-blockers in diabetics is warranted or sends the correct message to practicing physicians.

References

  1. ↵
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. . 2001; 37: 1053–1059.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
July 2001, Volume 38, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • References
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Diabetes, Hypertension, and Cardiovascular Disease: An Update
    Franz H. Messerli and Ehud Grossman
    Hypertension. 2001;38:e11, originally published September 1, 2001
    https://doi.org/10.1161/01.HYP.38.3.e11

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Diabetes, Hypertension, and Cardiovascular Disease: An Update
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Diabetes, Hypertension, and Cardiovascular Disease: An Update
    Franz H. Messerli and Ehud Grossman
    Hypertension. 2001;38:e11, originally published September 1, 2001
    https://doi.org/10.1161/01.HYP.38.3.e11
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured